Inspiration Biopharmaceuticals begins second phase III trial of OBI-1
OBI-1, an intravenous recombinant porcine factor VIII (FVIII) product which shows low cross reactivity to antihuman FVIII antibodies, is a replacement therapy, activating the intrinsic hemostatic pathway. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.